Literature DB >> 16674611

Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease.

B Bosche1, C Dohmen, P Impekoven, O Zaro-Weber, O Z Weber, D Reske, A Rubbert, A H Jacobs, H-F Petereit.   

Abstract

BACKGROUND: Interferon-beta (INF-beta) is effective and used in reducing exacerbation frequency and disease progression in multiple sclerosis. In certain circumstances, INF-beta can lead to rare side effects. AIMS OF THE STUDY: We report the case of a 34-year-old female patient satisfying the McDonald criteria of multiple sclerosis without showing typical pathologic changes in cerebrospinal fluid (CSF). After introduction of INF-beta treatment, she quickly developed further progression of her disseminated neurological symptoms and finally an ischemic cerebral infarction.
METHODS: Evaluation of the patient included arterial angiography, magnetic resonance and positron emission tomography, histopathological assessment as well as a broad spectrum of serum and CSF analysis.
RESULTS: All diagnostic evaluations and the clinical course revealed evidences for a primary angiitis of the CNS. We discuss the possible worsening due to inappropriate INF-beta treatment in cerebral angiitis promoting severe cerebrovascular insufficiency.
CONCLUSION: The authors suggest that all diagnostic multiple sclerosis criteria including typical CSF findings should be ascertained before INF-beta treatment is initiated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16674611     DOI: 10.1111/j.1600-0404.2006.00638.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

Review 1.  Central nervous system vasculitis in children.

Authors:  Susanne M Benseler
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.592

2.  Possible involvement of interferon beta in post-operative vasculitis restricted to the tumour bed: a case report.

Authors:  Tatsuya Abe; Kenji Sugita; Masaki Morishige; Kouhei Ohnishi; Keisuke Ishii; Tohru Kamida; Takamitsu Hikawa; Minoru Fujiki; Hidenori Kobayashi; Kenji Kashima; Shigeo Yokoyama
Journal:  Neurosurg Rev       Date:  2008-07-11       Impact factor: 3.042

3.  Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.

Authors:  Peter Joseph Jongen; Christian Sindic; Evert Sanders; Stanley Hawkins; Wim Linssen; Erik van Munster; Stephan Frequin; George Borm
Journal:  PLoS One       Date:  2011-10-25       Impact factor: 3.240

4.  Evaluating the safety of β-interferons in MS: A series of nested case-control studies.

Authors:  Hilda J I de Jong; Elaine Kingwell; Afsaneh Shirani; Jan Willem Cohen Tervaert; Raymond Hupperts; Yinshan Zhao; Feng Zhu; Charity Evans; Mia L van der Kop; Anthony Traboulsee; Paul Gustafson; John Petkau; Ruth Ann Marrie; Helen Tremlett
Journal:  Neurology       Date:  2017-05-12       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.